Department of Physiology, University of Medicine and Pharmacy "Iuliu Hațieganu", Cluj-Napoca 400000, Romania.
Cancer Biol Med. 2020 Feb 15;17(1):20-31. doi: 10.20892/j.issn.2095-3941.2019.0339.
With a constantly increasing incidence, cutaneous melanoma has raised the need for a better understanding of its complex microenvironment that may further guide therapeutic options. Melanoma is a model tumor in immuno-oncology. Inflammation represents an important hallmark of cancer capable of inducing and sustaining tumor development. The inflammatory process also orchestrates the adaptative immunosuppression of tumor cells that helps them to evade immune destruction. Besides its role in proliferation, angiogenesis, and apoptosis, cyclooxygenase-2 (COX-2) is a well-known promoter of immune suppression in melanoma. COX-2 inhibitors are closely involved in this condition. This review attempts to answer two controversial questions: is COX-2 a valuable prognostic factor? Among all COX-2 inhibitors, is celecoxib a suitable adjuvant in melanoma therapy?
随着发病率的不断上升，皮肤黑色素瘤的研究需要更好地了解其复杂的微环境，这可能进一步指导治疗选择。黑色素瘤是免疫肿瘤学中的一种典型肿瘤。炎症是癌症的一个重要标志，能够诱导和维持肿瘤的发展。炎症过程还协调了肿瘤细胞的适应性免疫抑制，帮助它们逃避免疫破坏。除了在增殖、血管生成和细胞凋亡中的作用外，环氧化酶-2（COX-2）也是黑色素瘤中免疫抑制的一个众所周知的促进因子。COX-2 抑制剂在这种情况下密切相关。这篇综述试图回答两个有争议的问题：COX-2 是一个有价值的预后因素吗？在所有 COX-2 抑制剂中，塞来昔布是黑色素瘤治疗的一种合适的辅助药物吗？
